<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576429</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02695-52</org_study_id>
    <nct_id>NCT04576429</nct_id>
  </id_info>
  <brief_title>Immune Profiles Evolution Under Immunotherapy for Melanoma</brief_title>
  <acronym>EPITHEM</acronym>
  <official_title>Immune Profiles Evolution in Patients Treated by Immunotherapy for Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study aims to compare the immune profiles (circulating cytokines&#xD;
      and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint&#xD;
      inhibitors in patients with melanoma treated in the adjuvant setting(cohort A) or in&#xD;
      metastatic setting(cohort B); and to study the association of these immune profiles with&#xD;
      relapse- or progression-free survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will analyse the association of biomarkers with relapse- or progression-free&#xD;
      survival of stage III or IV melanoma patients, divided in 3 sub-cohorts:&#xD;
&#xD;
        -  Patients treated in the adjuvant setting (cohort A): new user of immune checkpoint&#xD;
           blockers.&#xD;
&#xD;
        -  Patients treated in the metastatic setting (cohort B): - B1: new users of immune&#xD;
           checkpoint blockers; - B2: prevalent users of immune checkpoint blockers treated with&#xD;
           complementary radiotherapy.&#xD;
&#xD;
      For patients of cohort A and B1, immune profiles characteristics will be evaluated before&#xD;
      initiation of treatment (=baseline), and at each radiological evaluation of the tumour&#xD;
      response, up to maximum 12 months as duration.&#xD;
&#xD;
      The maximal duration of treatment will be 12 months for patients treated in the adjuvant&#xD;
      setting. For metastatic patients, the duration of treatment will be decided by physician&#xD;
      according to different factors (responses, progression, toxicities, ...).&#xD;
&#xD;
      For patients in cohort B2, the characteristics of the immune profiles will be evaluated&#xD;
      before radiotherapy initiation,, within 6 weeks after the end of radiotherapy, then at the 2&#xD;
      following radiological evaluations of the tumour response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of relapse/progression-free survival</measure>
    <time_frame>at 5 years</time_frame>
    <description>Will be noted: all progression and event of death. Survival rate will be calculated between the event's day and the beginning of anticancer treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunity profiles</measure>
    <time_frame>quarterly up to 12 months</time_frame>
    <description>ELISA Multiplex method will be used to analyse inflammatory human cytokines in plasma. This method will performe an assay 45-plex fixed panel :&#xD;
Analytes Included in the Assay&#xD;
CCL2/JE/MCP-1&#xD;
CCL3/MIP-1 alpha&#xD;
CCL4/MIP-1 beta&#xD;
CCL5/RANTES&#xD;
CCL11/Eotaxin&#xD;
CCL19/MIP-3 beta&#xD;
CCL20/MIP-3 alpha&#xD;
CD40 Ligand/TNFSF5&#xD;
CX3CL1/Fractalkine&#xD;
CXCL1/GRO alpha/KC/CINC-1&#xD;
CXCL2/GRO beta/MIP-2/CINC-3&#xD;
CXCL10/IP-10/CRG-2&#xD;
EGF&#xD;
FGF basic/FGF2/bFGF&#xD;
Flt-3 Ligand/FLT3L&#xD;
G-CSF&#xD;
GM-CSF&#xD;
Granzyme B&#xD;
IFN-alpha 2/IFNA2&#xD;
IFN-beta&#xD;
IFN-gamma&#xD;
IL-1 alpha/IL-1F1&#xD;
IL-1 beta/IL-1F2&#xD;
IL-1ra/IL-1F3&#xD;
IL-2&#xD;
IL-3&#xD;
IL-4&#xD;
IL-5&#xD;
IL-6&#xD;
IL-7&#xD;
IL-8/CXCL8&#xD;
IL-10&#xD;
IL-12 p70&#xD;
IL-13&#xD;
IL-15&#xD;
IL-17/IL-17A&#xD;
IL-17E/IL-25&#xD;
IL-33&#xD;
PD-L1/B7-H1&#xD;
PDGF-AA&#xD;
PDGF-AB/BB&#xD;
TGF-alpha&#xD;
TNF-alpha&#xD;
TRAIL/TNFSF10&#xD;
VEGF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>comparator group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>venous puncture</intervention_name>
    <description>Venous punctures will be performed:&#xD;
for patients of cohort A and B1:&#xD;
before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);&#xD;
between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);&#xD;
each 3 months up to 12 months.&#xD;
for patients of cohort B2:&#xD;
before the radiotherapy;&#xD;
within the 6 weeks after the end of radiotherapy;&#xD;
at the 2 following evaluations (every 3 months).</description>
    <arm_group_label>comparator group</arm_group_label>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tumoral biopsy</intervention_name>
    <description>Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.</description>
    <arm_group_label>comparator group</arm_group_label>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged ≥ 18 years;&#xD;
&#xD;
          -  Totally resected stage III or IV melanoma totally resected, treated with a immune&#xD;
             therapy (pembrolizumab or nivolumab ou other immune checkpoint inhibitors) as adjuvant&#xD;
             treatment;&#xD;
&#xD;
          -  Unresectable stage IIIC/D or IV metastatic melanoma, treated with immune therapy&#xD;
             (pembrolizumab or nivolumab or immune checkpoint inhibitors) which should be&#xD;
             associated by a radiotherapy ;&#xD;
&#xD;
          -  Patient has been informed about the study and signed the consent;&#xD;
&#xD;
          -  Affiliated to the French social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman;&#xD;
&#xD;
          -  Patient refusal;&#xD;
&#xD;
          -  Patient receiving a immunosuppressor;&#xD;
&#xD;
          -  Undergo a general corticotherapy of &gt; 10 mg/kg/day since more than 7 days;&#xD;
&#xD;
          -  Patient who participate to another blind interventional study receiving blinded&#xD;
             treatment;&#xD;
&#xD;
          -  Patient without any social protection by organization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa FUNCK-BRENTANO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermato-oncology department, Ambroise Paré hospital, APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-François EMILE, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pathology department, Ambroise Paré hospital, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa FUNCK-BRENTANO, MD</last_name>
    <phone>+33 (0)1 71 16 77 21</phone>
    <email>elisa.funck-brentano@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dermato-oncology department, Ambroise Paré hospital, APHP</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>immune profiles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

